Your browser doesn't support javascript.
loading
Short-term treatment with cholestyramine increases long-acting anticoagulant rodenticide clearance from rabbits without affecting plasma vitamin K1 levels or blood coagulation.
Muchiri, Ruth N; Rocha, Jackie; Tandon, Ankit; Chen, Yongmei Luo; Alemani, Rebecca; Ahmad, Intakhar; McDonald, Zachary; Lindeblad, Matthew; Rubinstein, Israel; van Breemen, Richard B; Feinstein, Douglas L.
Afiliação
  • Muchiri RN; Department of Pharmaceutical Sciences, Linus Pauling Institute, Oregon State University, Corvallis, Oregon 97331, USA.
  • Rocha J; Department of Anesthesiology, University of Illinois, Chicago, Illinois 60612, USA.
  • Tandon A; Department of Anesthesiology, University of Illinois, Chicago, Illinois 60612, USA.
  • Chen YL; Department of Pharmacology, University of Illinois, Chicago, Illinois 60612, USA.
  • Alemani R; Department of Anesthesiology, University of Illinois, Chicago, Illinois 60612, USA.
  • Ahmad I; Department of Anesthesiology, University of Illinois, Chicago, Illinois 60612, USA.
  • McDonald Z; Department of Anesthesiology, University of Illinois, Chicago, Illinois 60612, USA.
  • Lindeblad M; Department of Pharmacology, University of Illinois, Chicago, Illinois 60612, USA.
  • Rubinstein I; Department of Medicine, University of Illinois, Chicago, Illinois 60612, USA.
  • van Breemen RB; Research & Development Service, Jesse Brown VA Medical Center, Chicago, Illinois 60612, USA.
  • Feinstein DL; Department of Pharmaceutical Sciences, Linus Pauling Institute, Oregon State University, Corvallis, Oregon 97331, USA.
Toxicol Sci ; 200(1): 137-145, 2024 Jun 26.
Article em En | MEDLINE | ID: mdl-38603617
ABSTRACT
Administration of high-dose vitamin K1 (VK1) overcomes coagulopathy and bleeding elicited by acute poisoning with long-acting anticoagulant rodenticides (LAARs). However, long-term (months) treatment is required due to long LAAR biological half-lives that may lead to poor compliance and recurrent coagulopathy. The half-lives of LAARs are extended by slow metabolism, and similar to warfarin, are thought to undergo enterohepatic recirculation. We now show that treatment with the bile acid sequestrant cholestyramine (CSA) administered concomitantly with VK1 decreases plasma LAAR levels and increases LAAR fecal excretion. Daily CSA treatment for 14 days did not reduce plasma VK1 levels, or increase prothrombin time. Collectively, these data show that CSA accelerates LAAR clearance from rabbits without adverse effects on VK1 anticoagulation, and could provide an additional therapeutic option for treatment of LAAR poisoning.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vitamina K 1 / Rodenticidas / Coagulação Sanguínea / Resina de Colestiramina / Fezes / Anticoagulantes Limite: Animals Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vitamina K 1 / Rodenticidas / Coagulação Sanguínea / Resina de Colestiramina / Fezes / Anticoagulantes Limite: Animals Idioma: En Ano de publicação: 2024 Tipo de documento: Article